Figure 1From: Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trialClassification of patients into high- or low-risk group according to classic prognostic factors. ACPA, Anti–citrullinated protein antibodies; DAS28(CRP), Disease Activity Score in 28 joints based on C-reactive protein; RF, Rheumatoid factor.Back to article page